Veracyte, a cancer diagnostics company, completed the acquisition of C2i Genomics, a minimal residual disease detection company, for $95m. “Bringing C2i Genomics’ technology and team into Veracyte will allow us to make significant advances in our vision to transform cancer care for patients all over the world. C2i’s novel artificial intelligence-driven, whole-genome MRD platform will enable us to expand the value we deliver to clinicians and their patients, beginning with early cancer diagnosis and risk assessment, and now moving further along the patient journey into treatment monitoring and disease recurrence testing,” Marc Stapley, Veracyte CEO.